Physical activity counteracts increased whole-body protein breakdown in chronic obstructive pulmonary disease patients

2007 ◽  
Vol 18 (5) ◽  
pp. 557-564 ◽  
Author(s):  
A. M. W. Petersen ◽  
B. Mittendorfer ◽  
F. Magkos ◽  
M. Iversen ◽  
B. K. Pedersen
2000 ◽  
Vol 162 (4) ◽  
pp. 1488-1492 ◽  
Author(s):  
MARIËLLE P. K. J. ENGELEN ◽  
NICOLAAS E. P. DEUTZ ◽  
EMIEL F. M. WOUTERS ◽  
ANNEMIE M. W. J. SCHOLS

2006 ◽  
Vol 83 (4) ◽  
pp. 829-834 ◽  
Author(s):  
Erica PA Rutten ◽  
Frits ME Franssen ◽  
Marielle PKJ Engelen ◽  
Emiel FM Wouters ◽  
Nicolaas EP Deutz ◽  
...  

Metabolism ◽  
2012 ◽  
Vol 61 (9) ◽  
pp. 1289-1300 ◽  
Author(s):  
Mariëlle P.K.J. Engelen ◽  
Erica P.A. Rutten ◽  
Carmen L.N. De Castro ◽  
Emiel F.M. Wouters ◽  
Annemie M.W.J. Schols ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Danubia Sá-Caputo ◽  
Cintia Renata Gonçalves ◽  
Danielle Soares Morel ◽  
Eloá Moreira Marconi ◽  
Patrícia Fróes ◽  
...  

Background. Appropriate management, including pulmonary rehabilitation, associated with correct diagnosis of chronic obstructive pulmonary disease (COPD) in patients can contribute to improving clinical conditions of these patients. Physical activity is recommended for COPD patients. Whole-body vibration (WBV) is a modality of physical activity. Putting together the biological effects and safe use of WBV, it may be a potentially feasible intervention to add to pulmonary rehabilitation. The purpose of this investigation was to systematically review studies regarding the effects of WBV, as a component of the pulmonary rehabilitation, in patients with COPD.Results. A total of six publications met inclusion for review. There was evidence to support the beneficial use of WBV to improve functional performance of the lower limbs and quality of life. However, the appropriateness of and descriptors of WBV methods were poorly described.Conclusions. The results of this review support the use of WBV as a component of pulmonary rehabilitation to assist management of patients with COPD. However, future research should examine the dose-response curve and optimal dosing regimen of WBV according to standard reporting recommendations for people with COPD. Such an approach will allow comparison among studies and the potential of meta-analysis of randomized controlled trials.


2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Gamal Agmy ◽  
Manal A. Mahmoud ◽  
Azza Bahaa El-Din Ali ◽  
Mohamed Adam

Abstract Background Reversibility measured by spirometry in chronic obstructive pulmonary disease (COPD) is defined as an increase in forced expiratory volume in first second (FEV1) that is both more than 12% and 200 mL above the pre-bronchodilator value in response to inhaled bronchodilators. FEV1 only may not fully reverberate the changes caused by reduction in air trapping or hyperinflation. To date, the studies that examined the effect of inhaled bronchodilators (BD) on residual volume (RV) and total lung capacity (TLC) are limited. This study was carried out to assess the differences between flow and volume responses after bronchodilator reversibility testing in patients with different COPD GOLD stages (GOLD stage I to stage IV). Spirometry and whole body plethysmography were done before and 15 min after inhalation of 400 μg salbutamol. Results Majority (53.3%) of cases were volume responders, 18.7% were flow responders, 20% were flow and volume responders, and 8% were non responders. Significant increase in Δ FEV1% was found in 15% of cases while 55% showed a significant increase in Δ FVC (P= < 0.001). Mean difference of Δ FVC (L) post BD was significantly increased with advancing GOLD stage (P= 0.03). A cutoff point > 20% for Δ RV% had 70% sensitivity and 60% specificity and > 12% for Δ TLC% showed 90% sensitivity and 45% specificity for prediction of clinically significant response to BD based on FEV1. A cutoff point > 18% for Δ RV% had 78% sensitivity and 29% specificity and > 14% for Δ TLC% had 50% sensitivity and 70% specificity for prediction of clinically significant response to BD based on FVC. Conclusion ΔFEV1 underestimates the true effect of bronchodilators with advancing GOLD stage. Measurement of lung volumes in addition to the standard spirometric indices is recommended when determining bronchodilator response in COPD patients.


Sign in / Sign up

Export Citation Format

Share Document